METHODS	Enrolled patients were limited to those who did not achieve a very good partial remission ( VGPR ) following one or more induction regimens , and were randomized to receive a single escalating dose of bortezomib ( 1.0 , 1.3 , or 1.6 mg/m ( 2 ) ) either 24 hours before or 24 hours after high-dose melphalan .\